CPC C12N 15/1137 (2013.01) [A61K 31/7088 (2013.01); A61K 45/06 (2013.01); A61P 3/08 (2018.01); A61P 25/28 (2018.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2320/30 (2013.01)] | 17 Claims |
1. A method of treating Lafora disease in an individual having Lafora disease comprising administering to the individual a compound comprising a modified oligonucleotide consisting of 15 to 30 nucleosides, wherein the modified oligonucleotide has a nucleobase sequence at least 95% complementary to an equal length portion of the nucleobase sequence of SEQ ID NO: 6, wherein at least one internucleoside linkage of the modified oligonucleotide is a phosphorothioate internucleoside linkage, and wherein Lafora bodies are reduced in a cell in the individual, thereby treating the Lafora disease in the individual.
|